Our mission is to create a new category of therapeutics that repair the damage caused by devastating diseases. Our core innovation is the discovery of a global master regulator, the Innate Repair Receptors (IRR), that produces cellular and tissue repair in various disease states. Our lead compound in clinical development, Cibinetide, is focused on addressing unmet needs in neuroscience and diabetes complications.
We have developed an extensive peptide library of IRR activators, with in-vivo proof of concept efficacy for 10 unique compounds and an extensive catalogue of scientific literature in collaboration with leading academic researchers around the globe. Cibinetide, our lead product, is preparing for phase 3 initiation based upon prior studies which demonstrate regeneration of nerve fibers, reduction in pain, and functional improvements.
We have developed an extensive peptide library of IRR activators, with in-vivo proof of concept efficacy for 10 unique compounds and an extensive catalogue of scientific literature in collaboration with leading academic researchers around the globe. Cibinetide, our lead product, is preparing for phase 3 initiation based upon prior studies which demonstrate regeneration of nerve fibers, reduction in pain, and functional improvements.
Services
Dr Cerami has had a successful career applying detailed biochemical insights into understanding the pathogenesis of disease and translating these discoveries into novel therapeutic products that have wide clinical utility. He received his PhD from The Rockefeller University, completed a postdoctoral fellowship at Harvard Medical School, and has received three honorary doctorates.
Our mission to repair the damage caused by neurological diseases covers both the central and peripheral nervous system diseases. Neuropathy will damage the neurons of over 25% of Americans, and results in damaged nerves, pain, decreased functional mobility and increased mortality. Neuropathy is a significant driver of the opioid crisis and is a sequalae of the rampant diabetes epidemic impacting 70 million patients.
Inflammation with resultant tissue damage contributes to the pathogenesis of a broad range of human diseases, and plays a significant role in human aging, with increased risk for disease, poor physical functioning and mortality. Araim Pharmaceuticals lead compound, Cibinetide, is in clinical development addressing unmet needs in neuroscience and diabetes complications.
ARAIM is a privately held clinical stage pharmaceutical company developing treatments for Neurology and Diabetes related disorders through a proprietary novel platform technology. ARAIMs lead asset, Cibinetide, is in Phase 2 to delay disease progression and manage pain associated with Diabetic Neuropathy and Neuropathy associated with Sarcoidosis.
Reviews
Be the first to review Araim Pharmaceuticals.
Write a Review
